Anergis' allergy vaccine on course for Phase III testing
This article was originally published in Scrip
Executive Summary
Allergy vaccine-focused Anergis has reported strong immunology data from the Phase IIb study of its lead compound AllerT, a birch pollen treatment, and plans to embark of Phase III studies as quickly as it can.